The Queen Elizabeth Hospital

Iscalimab, a monoclonal antibody targeting an inflammatory pathway in Sjögren’s disease, showed improvements in clinician-reported disease activity and patient-reported dryness and fatigue in a Phase 2b trial, offering hope after prior drug failures.